Tranilast/allopurinol - Nuon Therapeutics

Drug Profile

Tranilast/allopurinol - Nuon Therapeutics

Alternative Names: NU-1618

Latest Information Update: 12 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nuon Therapeutics
  • Class Anthranilic acids; Antigouts; Antirheumatics; Purines; Small molecules; Uricosurics
  • Mechanism of Action Immunomodulators; SLC2A9 protein inhibitors; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Gout; Hyperuricaemia

Most Recent Events

  • 05 Jan 2011 Nuon Therapeutics completes the phase II TAnGO trial in Gout in USA (NCT01109121)
  • 23 Jun 2010 Efficacy and adverse events data from clinical trials in Hyperuricaemia released by Nuon Therapeutics
  • 23 Jun 2010 Pharmacodynamics data from a preclinical trial in Gout released by Nuon Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top